327 related articles for article (PubMed ID: 33563814)
21. Point mutations induced by foscarnet (PFA) in the human cytomegalovirus DNA polymerase.
Mousavi-Jazi M; Schloss L; Wahren B; Brytting M
J Clin Virol; 2003 Apr; 26(3):301-6. PubMed ID: 12637079
[TBL] [Abstract][Full Text] [Related]
22. Ribonucleotide reductase inhibitors hydroxyurea, didox, and trimidox inhibit human cytomegalovirus replication in vitro and synergize with ganciclovir.
Bhave S; Elford H; McVoy MA
Antiviral Res; 2013 Oct; 100(1):151-8. PubMed ID: 23933116
[TBL] [Abstract][Full Text] [Related]
23. PD0084430: a non-nucleoside inhibitor of human cytomegalovirus replication in vitro.
Meyer AL; Bruening EE; Dunkle WE; Booth RJ; Steinbaugh BA; Vara Prasad JV
Antiviral Res; 2001 Dec; 52(3):289-300. PubMed ID: 11675146
[TBL] [Abstract][Full Text] [Related]
24. Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.
Scott GM; Weinberg A; Rawlinson WD; Chou S
Antimicrob Agents Chemother; 2007 Jan; 51(1):89-94. PubMed ID: 17043128
[TBL] [Abstract][Full Text] [Related]
25. Opposite effect of two cytomegalovirus DNA polymerase mutations on replicative capacity and polymerase activity.
Martin M; Azzi A; Lin SX; Boivin G
Antivir Ther; 2010; 15(4):579-86. PubMed ID: 20587851
[TBL] [Abstract][Full Text] [Related]
26. Rapid simultaneous detection by real-time PCR of cytomegalovirus UL97 mutations in codons 460 and 520 conferring ganciclovir resistance.
Göhring K; Mikeler E; Jahn G; Hamprecht K
J Clin Microbiol; 2006 Dec; 44(12):4541-4. PubMed ID: 17035493
[TBL] [Abstract][Full Text] [Related]
27. Identification of resistance-associated HCMV UL97- and UL54-mutations and a UL97-polymporphism with impact on phenotypic drug-resistance.
Fischer L; Imrich E; Sampaio KL; Hofmann J; Jahn G; Hamprecht K; Göhring K
Antiviral Res; 2016 Jul; 131():1-8. PubMed ID: 27058773
[TBL] [Abstract][Full Text] [Related]
28. The discovery and development of filociclovir for the prevention and treatment of human cytomegalovirus-related disease.
Hussein ITM; Brooks J; Bowlin TL
Antiviral Res; 2020 Apr; 176():104710. PubMed ID: 31940473
[TBL] [Abstract][Full Text] [Related]
29. Point mutations in the DNA polymerase gene of human cytomegalovirus that result in resistance to antiviral agents.
Lurain NS; Thompson KD; Holmes EW; Read GS
J Virol; 1992 Dec; 66(12):7146-52. PubMed ID: 1331515
[TBL] [Abstract][Full Text] [Related]
30. Cytomegalovirus antiviral resistance associated with treatment induced UL97 (protein kinase) and UL54 (DNA polymerase) mutations.
Scott GM; Isaacs MA; Zeng F; Kesson AM; Rawlinson WD
J Med Virol; 2004 Sep; 74(1):85-93. PubMed ID: 15258973
[TBL] [Abstract][Full Text] [Related]
31. Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy.
Chou S
J Clin Virol; 2011 Apr; 50(4):287-91. PubMed ID: 21295516
[TBL] [Abstract][Full Text] [Related]
32. Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene.
Chou S
Antiviral Res; 2017 Feb; 138():57-60. PubMed ID: 27940027
[TBL] [Abstract][Full Text] [Related]
33. A point mutation in the human cytomegalovirus DNA polymerase gene confers resistance to ganciclovir and phosphonylmethoxyalkyl derivatives.
Sullivan V; Biron KK; Talarico C; Stanat SC; Davis M; Pozzi LM; Coen DM
Antimicrob Agents Chemother; 1993 Jan; 37(1):19-25. PubMed ID: 8381637
[TBL] [Abstract][Full Text] [Related]
34. Mass spectrometry-based comparative sequencing to detect ganciclovir resistance in the UL97 gene of human cytomegalovirus.
Posthuma CC; van der Beek MT; van der Blij-de Brouwer CS; van der Heiden PL; Marijt EW; Spaan WJ; Claas EC; Nederstigt C; Vossen AC; Snijder EJ; Kroes AC
J Clin Virol; 2011 May; 51(1):25-30. PubMed ID: 21388868
[TBL] [Abstract][Full Text] [Related]
35. [Modern ethiotropic chemotherapy of human cytomegalovirus infection: clinical effectiveness, molecular mechanism of action, drug resistance, new trends and prospects. Part 1.].
Andronova VL
Vopr Virusol; 2018; 63(5):202-211. PubMed ID: 30550096
[TBL] [Abstract][Full Text] [Related]
36. Ganciclovir resistance as a result of oral ganciclovir in a heart transplant recipient with multiple human cytomegalovirus strains in blood.
Baldanti F; Simoncini L; Sarasini A; Zavattoni M; Grossi P; Revello MG; Gerna G
Transplantation; 1998 Aug; 66(3):324-9. PubMed ID: 9721800
[TBL] [Abstract][Full Text] [Related]
37. New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by
Chou S; Satterwhite LE; Ercolani RJ
Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29914965
[TBL] [Abstract][Full Text] [Related]
38. 4-Oxo-4,7-dihydrothieno[2,3-b]pyridines as non-nucleoside inhibitors of human cytomegalovirus and related herpesvirus polymerases.
Schnute ME; Cudahy MM; Brideau RJ; Homa FL; Hopkins TA; Knechtel ML; Oien NL; Pitts TW; Poorman RA; Wathen MW; Wieber JL
J Med Chem; 2005 Sep; 48(18):5794-804. PubMed ID: 16134946
[TBL] [Abstract][Full Text] [Related]
39. DNA polymerases of herpesviruses and their inhibitors.
Piret J; Boivin G
Enzymes; 2021; 50():79-132. PubMed ID: 34861944
[TBL] [Abstract][Full Text] [Related]
40. The influence of mixed HCMV UL97 wildtype and mutant strains on ganciclovir susceptibility in a cell associated plaque reduction assay.
Eckle T; Jahn G; Hamprecht K
J Clin Virol; 2004 May; 30(1):50-6. PubMed ID: 15072754
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
